The opinion leaders and rising stars in Depressive disorders

Your weekly stakeholder digest, this week with leading experts in Depressive disorders. In this post we outline the opinion leaders, rising stars and other key stakeholders as well as investigator and clinical trials trends.

Read more

The leading opinion leaders and rising stars in Hepatitis C

Your weekly stakeholder digest, this week with leading experts in Hepatitis C. In this post we outline the opinion leaders, rising stars and other key stakeholders as well as investigator and clinical trials trends.

Read more

Opinion leaders, rising stars and leading investigators in Age-Related Macular Degeneration

Your weekly stakeholder digest, this week with leading experts in AMD. In this post we outline the opinion leaders, rising stars and other key stakeholders as well as investigator and clinical trials trends.

Read more

When Should You Start KOL Engagement?

Most pharmaceutical companies start engaging KOLs during Phase 3 clinical trials. In our newest blog we look at why this makes sense and also discuss situations when bringing KOLs on board earlier during drug development might be the way to go.

Read more

The opinion leaders and rising stars in HER2-positive Breast Cancer

Your weekly stakeholder digest, this week with leading experts in HER2-positive breast cancer. In this post we outline the opinion leaders, rising stars and other key stakeholders as well as investigator and clinical trials trends.

Read more

The leading investigators and rising stars in Rheumatoid arthritis

Your weekly stakeholder digest, this week with leading experts in Rheumatoid arthritis. In this post we outline the opinion leaders, rising stars and other key stakeholders as well as investigator and clinical trials trends.

Read more